Shots:
- QIAGEN has obtained European CE-IVDR certification for its QIAstat-Dx Meningitis/Encephalitis (ME) Panel to diagnose CNS infections, securing CE-IVDR approval for its entire QIAstat-Dx syndromic testing systems & panels
- The QIAstat-Dx ME Panel offers CNS infection coverage with 16 clinically relevant targets, incl. cytomegalovirus to meet current clinical needs & exclusive Streptococcus pyogenes detection to diagnose meningitis; launch expected in Sep 2025
- QIAstat-Dx requires no reagent preparation & minimal hands-on time, reducing contamination risk with limited, invasively collected samples like cerebrospinal fluid, & delivers fast, comprehensive results in about an hour
Ref: Businesswire| Image: Qiagen | Press Release
Related News:- Tracer Biotechnologies Collaborates with QIAGEN to Co-Develop and Commercialize Tracer dPCR & Tracer WGS for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
